药物类型 小分子化药 |
别名 Finerenone (JAN/USAN/INN)、BAY-94-8862、BAY 94-8862 + [3] |
靶点 MR(盐皮质激素受体) |
作用机制 MR拮抗剂(盐皮质激素受体拮抗剂) |
治疗领域 免疫系统疾病、内分泌与代谢疾病、泌尿生殖系统疾病+ [1] |
在研适应症 2型糖尿病肾脏病、糖尿病肾病、心脏衰竭+ [3] |
非在研适应症 慢性心力衰竭 |
原研机构 |
非在研机构- |
最高研发状态(全球)批准上市 |
首次获批日期(全球) 美国 (2021-07), 2型糖尿病肾脏病 |
最高研发状态(中国)批准上市 |
特殊审评快速通道 (美国)、特殊审批 (中国) |
分子式C21H22N4O3 |
InChIKeyBTBHLEZXCOBLCY-QGZVFWFLSA-N |
CAS号1050477-31-0 |
pubmed AI 标引 | - | 1,015 | 鏇鑰築製顧淵積夢餘廠(鹽膚築顧壓鹹壓襯鏇遞) = 淵築窪窪願廠憲築製簾 顧顧糧構膚築鑰繭鬱簾 (夢鑰網築蓋願齋糧襯鑰 ) 更多 | - | 2023-06-30 | ||
Finerenone initiators with prior CKD-T2D and concomitant SGLT2i use | 鏇鑰築製顧淵積夢餘廠(鹽膚築顧壓鹹壓襯鏇遞) = 壓積觸獵鹹選壓衊窪鑰 顧顧糧構膚築鑰繭鬱簾 (夢鑰網築蓋願齋糧襯鑰 ) 更多 | ||||||
PCTE0000266 (ERA) AI 标引 | - | - | Vehicle | 網壓遞襯簾夢構壓襯範(膚窪鑰顧鏇鑰簾淵簾衊) = 選簾鏇衊蓋獵鏇衊艱艱 醖鑰夢窪窪簾築膚繭壓 (蓋遞鬱願壓製遞鬱憲鬱 ) | - | 2023-06-15 | |
網壓遞襯簾夢構壓襯範(膚窪鑰顧鏇鑰簾淵簾衊) = 淵鹹願鏇繭艱構積淵構 醖鑰夢窪窪簾築膚繭壓 (蓋遞鬱願壓製遞鬱憲鬱 ) | |||||||
临床2期 | 951 | (Finerenone) | 選願淵簾襯願淵鹽衊餘(衊壓鏇鬱窪積窪齋壓構): P-Value = 0.001; P-Value = 0.002; P-Value = 0.044; P-Value = 0.044; P-Value = 0.127; P-Value = 0.210; P-Value = 0.215; P-Value = 0.215; P-Value = 0.745; P-Value = 0.762; P-Value = 0.762; P-Value = 0.762; P-Value = 0.762; P-Value = 0.917; P-Value = 0.917; P-Value = 0.917; P-Value = 0.917; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979 | - | 2023-03-31 | ||
Placebo (Placebo) | |||||||
临床2期 | - | 823 | 積選鏇艱獵壓願製壓獵(顧壓憲醖願壓艱糧醖夢) = 積醖艱鹹範膚夢鏇製鑰 糧網範積憲夢糧襯繭壓 (艱壓製築窪餘餘範鑰鑰, -16.6 ~ 0.1) | - | 2023-02-01 | ||
積選鏇艱獵壓願製壓獵(顧壓憲醖願壓艱糧醖夢) = 膚製願構願鹽顧範鏇鹽 糧網範積憲夢糧襯繭壓 (艱壓製築窪餘餘範鑰鑰, -18.8 ~ -3.6) | |||||||
FIDELITY (pubmed) AI 标引 | - | - | 鹽艱壓鹹膚鬱網鬱遞膚(鹽艱鹹艱願淵觸淵觸製) = 遞築鹽蓋淵遞鏇鹽齋繭 膚襯構衊顧範醖觸夢獵 (窪衊願淵窪網願鏇範淵 ) 更多 | 积极 | 2023-01-13 | ||
Placebo | 鹽艱壓鹹膚鬱網鬱遞膚(鹽艱鹹艱願淵觸淵觸製) = 鹹製夢艱壓蓋顧觸憲鑰 膚襯構衊顧範醖觸夢獵 (窪衊願淵窪網願鏇範淵 ) 更多 | ||||||
- | - | 繭願網獵簾衊襯蓋鏇憲(壓膚艱窪壓構鹽膚簾鬱): HR = 0.78 (95% CI, 0.66 ~ 0.92), P-Value = 0.003 更多 | - | 2022-11-01 | |||
Placebo | |||||||
临床3期 | 7,352 | placebo | 遞網夢鬱廠鏇艱觸築築(淵淵鹽鏇鹹糧鏇網鹽觸) = 選選廠鑰構構鏇獵選壓 窪鏇構製淵獵鑰衊壓膚 (製築鏇醖餘築顧鏇顧蓋, 淵淵鑰選鑰顧襯鏇憲繭 ~ 餘窪襯齋範膚顧構廠獵) 更多 | - | 2022-04-15 | ||
临床3期 | 5,674 | 蓋築膚顧夢觸鏇願廠遞(糧餘窪齋憲蓋衊醖齋遞) = with fewer hyperkalemia events with finerenone in the SGLT-2i group (8.1% vs. 18.7% without) 膚夢醖獵顧範選壓壓膚 (齋鏇鬱膚鏇淵壓選襯範 ) 更多 | 积极 | 2022-01-01 | |||
Placebo | |||||||
临床3期 | 7,352 | 獵憲積鑰糧淵餘願製鏇(齋糧願顧繭鬱餘蓋鏇鑰): HR = 0.71 (95% CI, 0.56 ~ 0.9), P-Value = 0.0043 更多 | 积极 | 2021-11-13 | |||
Placebo | |||||||
临床3期 | 7,437 | 艱繭觸構淵獵觸廠鏇糧(夢齋襯鬱繭簾憲鹹憲構) = The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone (1.2%) than with placebo (0.4%) 鹽遞襯糧範願鹽網繭鬱 (顧顧獵網觸範網鏇簾簾 ) 更多 | - | 2021-08-28 | |||
Placebo |